In hematological malignancies, researchers have discovered SPAG6 was upregulated in patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms (MPN). This evidence concerns the gene SPAG6 and myeloproliferative neoplasm.